Resources from the same session
LBA1 - Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study
Presenter: Javier Cortés
Session: Presidential symposium 1
Resources:
Abstract
Slides
Webcast
LBA2_PR - Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study
Presenter: Nicoletta Colombo
Session: Presidential symposium 1
Resources:
Abstract
Slides
Webcast
LBA3_PR - Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial
Presenter: Jason Luke
Session: Presidential symposium 1
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA2_PR
Presenter: Mansoor Raza Mirza
Session: Presidential symposium 1
Resources:
Slides
Webcast
Invited Discussant LBA3_PR
Presenter: Omid Hamid
Session: Presidential symposium 1
Resources:
Slides
Webcast